Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
59.00-0.48 (-0.81%)
At close: 4:00PM EDT
59.00 0.00 (0.00%)
After hours: 05:23PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close59.48
Open59.40
Bid56.04 x 800
Ask59.20 x 1300
Day's Range58.12 - 59.50
52 Week Range42.64 - 121.16
Volume689,410
Avg. Volume1,013,495
Market Cap5.616B
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-2.34
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est108.79
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FATE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fate Therapeutics, Inc.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Rating
    Fair Value
    Economic Moat
    9 months agoMorningstar
View more
  • Insider Monkey

    Hedge Funds Are Crazy About Fate Therapeutics Inc (FATE)

    We at Insider Monkey have gone over 873 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th. In this article, we look at what those funds think of Fate Therapeutics Inc (NASDAQ:FATE) based on that […]

  • GlobeNewswire

    Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting

    SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The o

  • GlobeNewswire

    Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

    Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK CellsSAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell p

Advertisement
Advertisement